Tolerability Study

Related by string. * tolerability : safety tolerability pharmacokinetics . safety tolerability pharmacokinetic . favorable tolerability . safety tolerability pharmacodynamics . tolerability pharmacokinetics . efficacy tolerability / studying . Studying . STUDY . studys . stu dy : Pre Feasibility Study . Case Study . Satisfaction Study SM . dose escalation study . Study Shows * *

Related by context. Frequent words. (Click for all words.) 68 Immunogenicity 67 Tolerability 65 Drug Candidate 65 Phase III Clinical Trial 64 Single Dose 64 Clinical Trial Results 64 Phase III Trial 64 II Clinical Trial 63 Novel Approach 63 Pivotal Study 63 Malaria Vaccine 62 Significantly Improves 62 Pivotal Trial 62 Monoclonal Antibody 62 Small Molecule 62 Improves Survival 62 Pediatric Patients 62 Hepatocellular Carcinoma 62 Preclinical Data 62 Well Tolerated 62 Completes Enrollment 61 Commences Phase 61 Anthrax Vaccine 61 Pivotal Phase III 61 Smallpox Vaccine 61 Inhibits 60 Renal Cell Carcinoma 60 Gastric Cancer 60 Immune Cells 60 Patient Enrollment 60 Initiate Phase 60 Brain Cells 60 Pharmacokinetics 60 Inflammatory Diseases 60 Holds Promise 60 Diagnostic Tests 60 Prostate Cancer Patients 60 Cholesterol Drug 60 Receives Orphan Drug Designation 60 Pivotal Phase 59 Patients Treated 59 Elderly Patients 59 FDA Clears 59 Bird Flu Vaccine 59 Cervical Cancer Vaccine 59 Initiates Phase II 59 Drug Resistant 59 Metastatic Colorectal Cancer 59 Tumor Growth 59 Presents Positive 59 Reduces Risk 59 Advanced Prostate Cancer 58 Gene Mutation 58 Monotherapy 58 FDA Accepts 58 Low Dose 58 Study Demonstrates 58 Chronic Hepatitis C 58 Recombinant Human 58 Patients Undergoing 58 Cholesterol Drugs 58 Helps Prevent 58 Mucosal 58 Blood Thinner 58 Influenza Virus 58 Meta Analysis 58 Initiates Phase 58 Diabetic Neuropathy 58 Clinical Study 58 Metastatic Melanoma 58 Epidermal Growth Factor Receptor 58 Cognitive Function 57 Suppresses 57 Shows Promise 57 Announces FDA Clearance 57 FDA Clearance 57 Influenza Vaccine 57 Targeted Therapy 57 Patent Covering 57 Survival Rates 57 Int J 57 Eculizumab 57 Diabetic Patients 57 Pulmonary Arterial Hypertension 57 Blood Vessels 57 Inhaled Insulin 57 Epratuzumab 57 Tesetaxel 57 Chronic Hepatitis B 57 Heart Failure Patients 56 Cyclophosphamide 56 Induces 56 Bone Mineral Density 56 RNAi Therapeutics 56 Combination Therapy 56 Extended Release 56 Cancer Cells 56 Prostate Cancer Treatment 56 Radiation Exposure 56 Acute Ischemic Stroke 56 Bioavailability

Back to home page